NCT03893955

Who might be able to join this trial:

• Your liver, kidneys, and blood counts must be at healthy enough levels, as shown by recent lab tests.
• You must be generally well enough to carry out light activity and care for yourself (a doctor will assess this using a standard scale called ECOG, scoring 0 or 1).
• (Dose-Escalation – Arm A): You have an advanced solid tumour that has continued to grow or spread after trying standard treatments, or you were unable to tolerate or chose not to have those treatments.
• (Dose-Escalation – Arm B): You have been diagnosed with non-small-cell lung cancer (NSCLC), confirmed by a tissue or cell sample, and your cancer got worse during or after treatment with a specific type of immunotherapy (anti-PD-1 or PD-L1 therapy) and a platinum-based chemotherapy.
• (Dose-Expansion – Arms 1, 2 & 3): You have been diagnosed with a specific type of breast cancer called triple-negative breast cancer (TNBC), confirmed by a tissue or cell sample, your cancer has progressed after at least one treatment including a taxane chemotherapy drug in the advanced or recurrent setting, and you have never received immunotherapy.
• (Dose-Expansion – Arm 4): You have confirmed TNBC, have not yet received any anti-cancer treatment for TNBC, and a lab test on your tumour tissue shows a protein called PD-L1 is not present.
• (Dose-Expansion – Arm 5): You have confirmed NSCLC and your cancer got worse during or after immunotherapy (anti-PD-1 or PD-L1 therapy) and platinum-based chemotherapy.

Who may not be able to join:

• You have a history of inflammatory bowel disease or inflammation of the lungs (pneumonitis).
• You have cancer that has spread to the brain or spinal cord and is not currently under control.
• You have a second, separate cancer that is serious, requires treatment, or is not currently stable.
• You have had a major operation within the last 28 days before starting the trial, or your surgical wound has not fully healed.
• You previously received an immunotherapy drug targeting PD-1 or PD-L1 and experienced any of the following: a severe immune-related side effect (Grade 3 or worse); needed steroid tablets or injections to treat a side effect; had an allergic reaction to the immunotherapy drug; or had to stop taking the immunotherapy drug because of side effects.

Important: Always verify eligibility with the trial site directly before applying.